Background: Uncertainty surrounds why hepatitis C virus (HCV) is concentrated among HIV-positive men who have sex with men (MSM). We used mathematical modelling to explore reasons for these infection patterns, and implications for HCV treatment-as-prevention. Methods: Using a joint MSM HIV/HCV transmission model parameterized with UK behavioural data, we considered how biological (heightened HCV infectivity and reduced spontaneous clearance among HIV-positive MSM) and/or behavioural factors (preferential sexual mixing by HIV status and risk heterogeneity) could concentrate HCV infection in HIV-positive MSM as commonly observed (5-20 times the HCV prevalence in HIV-negative MSM; defined as the HCV ratio). We explored how HCV treatment-as-prevention impact varies under differing HCV ratios. Results: Biological factors produced low HCV ratios (< 3), not explaining the skewed epidemic. However, combining preferential mixing by HIV status with sexual risk behaviour heterogeneity produced high HCV ratios (> 10) that were highly sensitive to both factors. Irrespective of the HCV ratio or behavioural/biological factors, HCV treatment of HIV-diagnosed MSM markedly reduced the HCV prevalence among HIV-positive MSM, but less impact was achieved among all MSM for lower HCV ratios. Conclusions: Sexual behaviour patterns likely drive observed HCV infection patterns among HIV-positive MSM. Changes in these patterns could disseminate HCV amongst HIV-negative MSM, limiting the impact of targeting HCV treatment to HIV-diagnosed MSM.
Background: Uncertainty surrounds why hepatitis C virus (HCV) is concentrated among HIV-positive men who have sex with men (MSM). We used mathematical modelling to explore reasons for these infection patterns, and implications for HCV treatment-as-prevention. Methods: Using a joint MSM HIV/HCV transmission model parameterized with UK behavioural data, we considered how biological (heightened HCV infectivity and reduced spontaneous clearance among HIV-positive MSM) and/or behavioural factors (preferential sexual mixing by HIV status and risk heterogeneity) could concentrate HCV infection in HIV-positive MSM as commonly observed (5-20 times the HCV prevalence in HIV-negative MSM; defined as the HCV ratio). We explored how HCV treatment-as-prevention impact varies under differing HCV ratios. Results: Biological factors produced low HCV ratios (< 3), not explaining the skewed epidemic. However, combining preferential mixing by HIV status with sexual risk behaviour heterogeneity produced high HCV ratios (> 10) that were highly sensitive to both factors. Irrespective of the HCV ratio or behavioural/biological factors, HCV treatment of HIV-diagnosed MSM markedly reduced the HCV prevalence among HIV-positive MSM, but less impact was achieved among all MSM for lower HCV ratios. Conclusions: Sexual behaviour patterns likely drive observed HCV infection patterns among HIV-positive MSM. Changes in these patterns could disseminate HCV amongst HIV-negative MSM, limiting the impact of targeting HCV treatment to HIV-diagnosed MSM.
Authors: Andrew Anglemyer; George W Rutherford; Rachel C Baggaley; Matthias Egger; Nandi Siegfried Journal: Cochrane Database Syst Rev Date: 2011-08-10
Authors: D L Thomas; J Astemborski; D Vlahov; S A Strathdee; S C Ray; K E Nelson; N Galai; K R Nolt; O Laeyendecker; J A Todd Journal: J Infect Dis Date: 2000-03 Impact factor: 5.226
Authors: Jason Grebely; Jesse D Raffa; Calvin Lai; Mel Krajden; Brian Conway; Mark W Tyndall Journal: Can J Gastroenterol Date: 2007-07 Impact factor: 3.522
Authors: Paul J Birrell; O Noel Gill; Valerie C Delpech; Alison E Brown; Sarika Desai; Tim R Chadborn; Brian D Rice; Daniela De Angelis Journal: Lancet Infect Dis Date: 2013-02-01 Impact factor: 25.071
Authors: Margaret T May; Mark Gompels; Valerie Delpech; Kholoud Porter; Chloe Orkin; Stephen Kegg; Phillip Hay; Margaret Johnson; Adrian Palfreeman; Richard Gilson; David Chadwick; Fabiola Martin; Teresa Hill; John Walsh; Frank Post; Martin Fisher; Jonathan Ainsworth; Sophie Jose; Clifford Leen; Mark Nelson; Jane Anderson; Caroline Sabin Journal: AIDS Date: 2014-05-15 Impact factor: 4.177
Authors: Adam Trickey; Hannah Fraser; Aaron G Lim; Amy Peacock; Samantha Colledge; Josephine G Walker; Janni Leung; Jason Grebely; Sarah Larney; Natasha K Martin; Matthew Hickman; Louisa Degenhardt; Margaret T May; Peter Vickerman Journal: Lancet Gastroenterol Hepatol Date: 2019-04-10
Authors: Natasha K Martin; Klaus Jansen; Matthias An der Heiden; Christoph Boesecke; Anders Boyd; Knud Schewe; Axel Baumgarten; Thomas Lutz; Stefan Christensen; Alexander Thielen; Stefan Mauss; Jürgen K Rockstroh; Britt Skaathun; Patrick Ingiliz Journal: J Infect Dis Date: 2019-10-08 Impact factor: 5.226
Authors: Louis Macgregor; Zoe Ward; Natasha K Martin; Jane Nicholls; Monica Desai; Ford Hickson; Peter Weatherburn; Matthew Hickman; Peter Vickerman Journal: J Viral Hepat Date: 2021-04-01 Impact factor: 3.517
Authors: Bilal Khan; Ian Duncan; Mohamad Saad; Daniel Schaefer; Ashly Jordan; Daniel Smith; Alan Neaigus; Don Des Jarlais; Holly Hagan; Kirk Dombrowski Journal: PLoS One Date: 2018-11-29 Impact factor: 3.240
Authors: Louis Macgregor; Monica Desai; Natasha K Martin; Jane Nicholls; Ford Hickson; Peter Weatherburn; Matthew Hickman; Peter Vickerman Journal: EClinicalMedicine Date: 2019-12-19
Authors: Britt Skaathun; Annick Borquez; Antonio Rivero-Juarez; Sanjay R Mehta; Francisco Tellez; Manuel Castaño-Carracedo; Dolores Merino; Rosario Palacios; Juan Macías; Antonio Rivero; Natasha K Martin Journal: BMC Infect Dis Date: 2020-08-08 Impact factor: 3.090